Please login to the form below

Not currently logged in
Email:
Password:

Profil Institute appoints former Amylin CEO

Dan Bradbury joins board of diabetes company

The Profil Institute for Clinical Research has appointed Dan Bradbury to its board of directors.

Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

He is currently a managing member of the life sciences consultancy firm BioBrit.

Dr Marcus Hompesch, CEO of diabetes-focused Profil Institute said: “Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry.”

He added: “With Mr Bradbury's considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company's strategic course.”

7th November 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....